RxDoctor Payments Data

Tamy Buckel, MD

Dermatology · Chestertown, MDNPI 1467406553

Payments from drug & device makers

$905in general payments, 2019–2025

Across 34 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$331
  • AbbVie$138
  • Bristol Myers Squibb$110
  • Dermavant Sciences, Inc.$94
  • UCB, Inc.$75
  • Regeneron Healthcare Solutions, Inc.$60
  • plus $99 from 6 others

What the payments were for

  • Food & beverage$61368%
  • Education$29232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$905 in reported general payments places this provider in the 35th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland

Medicare billing

Part B allowed, 2024
$252,668
Medicare patients
1,129
Services billed
3,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab59$221,712
OtezlaApremilast13$62,390
Pimecrolimus12$2,924
Clobetasol Propionate30$2,097
Fluorouracil28$1,612
Minocycline Hcl14$1,375
Doxycycline Hyclate31$1,118
Clindamycin Phosphate16$1,098
Metronidazole21$950
Doxepin Hcl13$868
Triamcinolone Acetonide87$833
Ketoconazole40$692
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip20$538
ValacyclovirValacyclovir Hcl19$312
Hydrocortisone28$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$13$62,39013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 306 dermatology providers in Maryland.

Other dermatology in Chestertown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →